Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Diabetologia
Published in: Diabetologia 5/2005

01-05-2005 | Review

Clinical significance of the physicochemical properties of LDL in type 2 diabetes

Authors: P. G. Scheffer, T. Teerlink, R. J. Heine

Published in: Diabetologia | Issue 5/2005

Login to get access

Abstract

Atherosclerosis is the leading cause of death in type 2 diabetes. LDL cholesterol and atherosclerosis are related, both in healthy people and those with diabetes; however, people with diabetes are more prone to atheroma, even though their LDL cholesterol levels are similar to those in their non-diabetic peers. This is because LDL particles are modified in the presence of diabetes to become more atherogenic. These modifications include glycation in response to high plasma glucose levels; oxidative reactions mediated by increased oxidative stress; and transfer of cholesterol ester, which makes the particles smaller and denser. The latter modification is strongly associated with hypertriglyceridaemia. Oxidatively and non-oxidatively modified LDL is involved in plaque formation, and may thus contribute to the accelerated atherosclerosis. This review discusses the techniques currently used to determine the physicochemical properties of LDL, and examines the evidence that modification of these properties plays a role in the accelerated atherosclerosis associated with type 2 diabetes.
Literature
1.
Folsom AR, Szklo M, Stevens J, Liao F, Smith R, Eckfeldt JH (1997) A prospective study of coronary heart disease in relation to fasting insulin, glucose, and diabetes. The Atherosclerosis Risk in Communities (ARIC) Study. Diabetes Care 20:935–942PubMed
2.
Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M (1998) Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 339:229–234CrossRefPubMed
3.
Keaney JF, Loscalzo J (1999) Diabetes, oxidative stress, and platelet activation. Circulation 99:189–191
4.
Turner RC, Millns H, Neil HAW et al (1998) Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23). BMJ 316:823–828
5.
Collins R, Armitage J, Parish S, Sleigh P, Peto R (2003) MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 361:2005–2016CrossRefPubMed
6.
Taskinen MR (2003) Diabetic dyslipidaemia: from basic research to clinical practice. Diabetologia 46:733–749CrossRef
7.
Brunzell JD, Ayyobi AF (2003) Dyslipidemia in the metabolic syndrome and type 2 diabetes mellitus. Am J Med 115(Suppl 8A):24S–28S
8.
Östgren CJ, Lindblad U, Ranstam J, Melander A, Råstam L (2002) Glycaemic control, disease duration and beta-cell function in patients with Type 2 diabetes in a Swedish community. Skaraborg Hypertension and Diabetes Project. Diabet Med 19:125–129
9.
Heine RJ, Dekker JM (2002) Beyond postprandial hyperglycaemia: metabolic factors associated with cardiovascular disease. Diabetologia 45:461–475
10.
Schaefer EJ, McNamara JR, Shah PK et al (2002) Elevated remnant-like particle cholesterol and triglyceride levels in diabetic men and women in the Framingham Offspring Study. Diabetes Care 25:989–994
11.
Esterbauer H, Gebicki J, Puhl H, Jürgens G (1992) The role of lipid peroxidation and antioxidants in oxidative modification of LDL. Free Radic Biol Med 13:341–390
12.
Teerlink T, Scheffer PG, Bakker SJL, Heine RJ (2004) Combined data from LDL composition and size measurement are compatible with a discoid particle shape. J Lipid Res 45:954–966
13.
Scheffer PG, Bakker SJL, Heine RJ, Teerlink T (1997) Measurement of low-density lipoprotein particle size by high-performance gel-filtration chromatography. Clin Chem 43:1904–1912
14.
Austin MA, Mykkänen L, Kuusisto J et al (1995) Prospective study of small LDLs as a risk factor for non-insulin dependent diabetes mellitus in elderly men and women. Circulation 92:1770–1778
15.
Riemens S, Van Tol A, Sluiter W, Dullaart R (1998) Elevated plasma cholesteryl ester transfer in NIDDM: relationships with apolipoprotein B-containing lipoproteins and phospholipid transfer protein. Atherosclerosis 140:71–79
16.
Bossé Y, Vohl MC, Després JP et al (2003) Heritability of LDL peak particle diameter in the Quebec Family Study. Genet Epidemiol 25:375–381
17.
Krauss RM, Burke DJ (1982) Identification of multiple subclasses of plasma low density lipoproteins in normal humans. J Lipid Res 23:97–104
18.
Forte TM, Nordhausen RW (1986) Electron microscopy of negatively stained lipoproteins. Methods Enzymol 128:442–457
19.
Chatterton JE, Schlapfer P, Bütler E et al (1995) Identification of apolipoprotein B100 polymorphisms that affect low-density lipoprotein metabolism: description of a new approach involving monoclonal antibodies and dynamic light scattering. Biochemistry 34:9571–9580
20.
Scheffer PG, Bakker SJL, Heine RJ, Teerlink T (1998) Measurement of LDL particle size in whole plasma and serum by high performance gel-filtration chromatography using a fluorescent lipid probe. Clin Chem 44:2148–2151
21.
Blake GJ, Otvos JD, Rifai N, Ridker PM (2002) Low-density lipoprotein particle concentration and size as determined by nuclear magnetic resonance spectroscopy as predictors of cardiovascular disease in women. Circulation 106:1930–1937
22.
Van Antwerpen R (2004) Preferred orientations of LDL in vitreous ice indicate a discoid shape of the lipoprotein particle. Arch Biochem Biophys 432:122–127
23.
Witte DR, Taskinen MR, Perttunen-Nio H, Van Tol A, Livingstone S, Colhoun HM (2004) Study of agreement between LDL size as measured by nuclear magnetic resonance and gradient gel electrophoresis. J Lipid Res 45:1069–1076
24.
Wägner AM, Jorba O, Rigla M, Alonso E, Ordónez-Llanos J, Pérez A (2002) LDL-cholesterol/apolipoprotein B ratio is a good predictor of LDL phenotype B in type 2 diabetes. Acta Diabetol 39:215–220
25.
Tallis GA, Shephard MDS, Sobecki S, Whiting MJ (1995) The total apolipoprotein B/LDL-cholesterol ratio does not predict LDL particle size. Clin Chim Acta 240:63–73
26.
Björnheden T, Babyi A, Bondjers G, Wiklund O (1996) Accumulation of lipoprotein fractions and subfractions in the arterial wall, determined in an in vitro perfusion system. Atherosclerosis 123:43–56
27.
Anber V, Griffin BA, McConnell M, Packard CJ, Shepherd J (1996) Influence of plasma lipid and LDL-subfraction profile on the interaction between low density lipoprotein with human arterial wall proteoglycans. Atherosclerosis 124:261–271
28.
Chait A, Brazg RL, Tribble DL, Krauss RM (1993) Susceptibility of small, dense, low-density lipoproteins to oxidative modification in subjects with the atherogenic lipoprotein phenotype, pattern B. Am J Med 94:350–356
29.
De Graaf J, Hak-Lemmers HLM, Hectors MPC, Demacker PNM, Hendriks JCM, Stalenhoef AFH (1991) Enhanced susceptibility to in vitro oxidation of the dense low density lipoprotein subfraction in healthy subjects. Arterioscler Thromb 11:298–306
30.
Dejager S, Bruckert E, Chapman MJ (1993) Dense low density lipoprotein subspecies with diminished oxidative resistance predominate in combined hyperlipidemia. J Lipid Res 34:295–308
31.
Campos H, Arnold KS, Balestra ME, Innerarity TL, Krauss RM (1996) Differences in receptor binding of LDL subfractions. Arterioscler Thromb Vasc Biol 16:794–801
32.
Vakkilainen J, Steiner G, Ansquer JC et al (2003) Relationships between low-density lipoprotein particle size, plasma lipoproteins, and progression of coronary artery disease. The Diabetes Atherosclerosis Intervention Study (DAIS). Circulation 107:1733–1737CrossRefPubMed
33.
Campos H, Genest JJ, Blijlevens E et al (1992) Low density lipoprotein particle size and coronary artery disease. Arterioscler Thromb 12:187–195
34.
Williams PT, Superko HR, Haskell WL et al (2003) Smallest LDL particles are most strongly related to coronary disease progression in men. Arterioscler Thromb Vasc Biol 23:314–321
35.
Lamarche B, Tchernof A, Moorjani S et al (1997) Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men. Prospective results from the Quebec Cardiovascular Study. Circulation 95:69–75
36.
Stampfer MJ, Krauss RM, Ma J et al (1996) A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction. JAMA 276:882–888
37.
Singh ATK, Rainwater DL, Haffner SM et al (1995) Effect of diabetes on lipoprotein size. Arterioscler Thromb Vasc Biol 15:1805–1811
38.
Scheffer PG, Bos G, Volwater HG, Dekker JM, Heine RJ, Teerlink T (2003) Associations of LDL size with in vitro oxidizability and plasma levels of in vivo oxidized LDL in type 2 diabetic patients. Diabet Med 20:563–567CrossRef
39.
Suehiro T, Ohguro T, Sumiyoshi R et al (1995) Relationship of low-density lipoprotein particle size to plasma lipoproteins, obesity, and insulin resistance in Japanese men. Diabetes Care 18:333–338
40.
Williams K, Sniderman AD, Sattar N, D’Agostino R Jr, Wagenknecht LE, Haffner SM (2003) Comparison of the associations of apolipoprotein B and low-density lipoprotein cholesterol with other cardiovascular risk factors in the Insulin Resistance Atherosclerosis Study (IRAS). Circulation 108:2312–2316
41.
Jiang R, Schulze MB, Li T et al (2004) Non-HDL cholesterol and apolipoprotein B predict cardiovascular disease events among men with type 2 diabetes. Diabetes Care 27:1991–1997
42.
Grundy SM (1995) Role of low-density lipoproteins in atherogenesis and development of coronary heart disease. Clin Chem 41:139–146
43.
Holvoet P, Vanhaecke J, Janssens S, Van de Werf F, Collen D (1998) Oxidized LDL and malondialdehyde-modified LDL in patients with acute coronary syndromes and stable coronary artery disease. Circulation 98:1487–1494
44.
Lyons TJ, Li W, Wells-Knecht MC, Jokl R (1994) Toxicity of mildly modified low-density lipoproteins to cultured retinal capillary endothelial cells and pericytes. Diabetes 43:1090–1095
45.
Quinn MT, Parthasarathy S, Fong LG, Steinberg D (1987) Oxidatively modified low density lipoproteins: a potential role in recruitment and retention of monocyte/macrophages during atherogenesis. Proc Natl Acad Sci U S A 84:2995–2998
46.
Sakai M, Miyazaki A, Hakamata H et al (1996) Lysophosphatidylcholine potentiates the mitogenic activity of modified LDL for human monocyte-derived macrophages. Arterioscler Thromb Vasc Biol 16:600–605
47.
48.
Skrha J, Hodinar A, Kvasnicka J, Hilgertova J (1996) Relationship of oxidative stress and fibrinolysis in diabetes mellitus. Diabet Med 13:800–805
49.
Keaney JF, Larson MG, Vasan RS et al (2003) Obesity and systemic oxidative stress: clinical correlates of oxidative stress in the Framingham Study. Arterioscler Thromb Vasc Biol 23:434–439
50.
Yoshida H, Ishikawa T, Nakamura H (1997) Vitamin E/lipid peroxide ratio and susceptibility of LDL to oxidative modification in non-insulin-dependent diabetes mellitus. Arterioscler Thromb Vasc Biol 17:1438–1446
51.
Akkus I, Kalak S, Vural H et al (1996) Leukocyte lipid peroxidation, superoxide dismutase, glutathione peroxidase and serum and leukocyte vitamin C levels of patients with type II diabetes mellitus. Clin Chim Acta 244:221–227
52.
Esterbauer H, Striegl G, Puhl H, Rotheneder M (1989) Continuous monitoring of in vitro oxidation of human low density lipoprotein. Free Rad Res Commun 6:67–75
53.
Scheffer PG, Henry RMA, Wever EJM et al (2004) LDL oxidative modifications in well or moderately controlled type 2 diabetes. Diabetes Metab Res Rev 20:298–304
54.
Cazzolato G, Avogaro P, Bittolo-Bon G (1991) Characterization of a more electronegatively charged LDL subfraction by ion exchange HPLC. Free Radic Biol Med 11:247–253
55.
56.
Tanaga K, Bujo H, Inoue M et al (2002) Increased circulating malondialdehyde-modified LDL levels in patients with coronary artery diseases and their association with peak sizes of LDL particles. Arterioscler Thromb Vasc Biol 22:662–666
57.
Scheffer PG, Bakker SJL, Musch EE, Popp-Snijders C, Heine RJ, Teerlink T (2000) Comparison of three methods for measuring LDL resistance against copper-induced oxidation. Clin Chem 46:291–294
58.
Regnström J, Nilsson J, Tornvall P, Landou C, Hamsten A (1992) Susceptibility to low-density lipoprotein oxidation and coronary atherosclerosis in man. Lancet 339:1183–1186
59.
Dimitriadis E, Griffin M, Owens D, Johnson A, Collins P, Tomkin GH (1995) Oxidation of low-density lipoprotein in NIDDM: its relationship to fatty acid composition. Diabetologia 38:1300–1306
60.
Schwenke DC, D’Agostino RB Jr, Goff DC Jr, Karter AJ, Rewers MJ, Wagenknecht LE (2003) Differences in LDL oxidizability by glycemic status: the Insulin Resistance Atherosclerosis Study. Diabetes Care 26:1449–1455
61.
Ahotupa M, Marniemi J, Lehtimäki T et al (1998) Baseline diene conjugation in LDL lipids as a direct measure of in vivo LDL oxidation. Clin Biochem 31:257–261
62.
Gavella M, Lipovac V, Car A, Vucic M (2002) Baseline diene conjugation in LDL lipids from newly diagnosed type 2 diabetic patients. Diabetes Metab 28:391–396
63.
Reaven P, Parthasarathy S, Grasse BJ, Miller E, Steinberg D, Witztum JL (1993) Effects of oleate-rich and linoleate-rich diets on the susceptibility of low density lipoprotein to oxidative modification in mildly hypercholesterolemic subjects. J Clin Invest 91:668–676
64.
Gumbiner B, Low CC, Reaven PD (1998) Effects of a monounsaturated fatty acid-enriched hypocaloric diet on cardiovascular risk factors in obese patients with type 2 diabetes. Diabetes Care 21:9–15
65.
Scheffer PG, Bakker SJL, Popp-Snijders C, Heine RJ, Schutgens RBH, Teerlink T (2001) Composition of LDL as determinant of its susceptibility to in vitro oxidation in patients with well-controlled type 2 diabetes. Diabetes Metab Res Rev 17:459–466
66.
Mol MJTM, De Rijke YB, Demacker PNM, Stalenhoef AFH (1997) Plasma levels of lipid and cholesterol oxidation products and cytokines in diabetes mellitus and cigarette smoking: effects of vitamin E treatment. Atherosclerosis 129:169–176CrossRef
67.
Moro E, Zambon C, Pianetti S, Cazzolato G, Pais M, Bittolo BG (1998) Electronegative low density lipoprotein subform (LDL-) is increased in type 2 (non-insulin-dependent) microalbuminuric diabetic patients and is closely associated with LDL susceptibility to oxidation. Acta Diabetol 35:161–164
68.
Kopprasch S, Pietzsch J, Kuhlisch E et al (2002) In vivo evidence for increased oxidation of circulating LDL in impaired glucose tolerance. Diabetes 51:3102–3106
69.
Ujihara N, Sakka Y, Takeda M et al (2002) Association between plasma oxidized low-density lipoprotein and diabetic nephropathy. Diabetes Res Clin Pract 58:109–114
70.
Metso S, Loimaala A, Mercuri MF et al (2004) Circulating oxidized low-density lipoprotein and common carotid artery intima–media thickness in a random sample of middle-aged men. J Biomed Sci 11:356–361
71.
Shimada K, Mokuno H, Matsunaga E et al (2004) Predictive value of circulating oxidized LDL for cardiac events in type 2 diabetic patients with coronary artery disease. Diabetes Care 27:843–844
72.
Wallenfeldt K, Fagerberg B, Wikstrand J, Hulthe J (2004) Oxidized low-density lipoprotein in plasma is a prognostic marker of subclinical atherosclerosis development in clinically healthy men. J Intern Med 256:413–420
73.
Mironova MA, Klein RL, Virella GT, Lopes-Virella MF (2000) Anti-modified LDL antibodies, LDL-containing immune complexes, and susceptibility of LDL to in vitro oxidation in patients with type 2 diabetes. Diabetes 49:1033–1041
74.
Bellomo G, Maggi E, Poli M, Agosta FG, Bollati P, Finardi G (1995) Autoantibodies against oxidatively modified low-density lipoproteins in NIDDM. Diabetes 44:60–66
75.
Hsu RM, Devaraj S, Jialal I (2002) Autoantibodies to oxidized low-density lipoprotein in patients with type 2 diabetes mellitus. Clin Chim Acta 317:145–150
76.
Karvonen J, Päivänsalo M, Kesäniemi YA, Hörkkö S (2003) Immunoglobulin M type of autoantibodies to oxidized low-density lipoprotein has an inverse relation to carotid artery atherosclerosis. Circulation 108:2107–2112
77.
Lyons TJ, Jenkins AJ (1997) Lipoprotein glycation and its metabolic consequences. Curr Opin Lipidol 8:174–180
78.
Moro E, Alessandrini P, Zambon C et al (1999) Is glycation of low density lipoproteins in patients with type 2 diabetes mellitus a LDL pre-oxidative condition? Diabet Med 16:663–669
79.
Witztum JL, Mahoney EM, Branks MJ, Fisher M, Elam R, Steinberg D (1982) Nonenzymatic glucosylation of low-density lipoprotein alters its biologic activity. Diabetes 31:283–291
80.
Kawamura M, Heinecke JW, Chait A (1994) Pathophysiological concentrations of glucose promote oxidative modification of low density lipoprotein by a superoxide-dependent pathway. J Clin Invest 94:771–778
81.
Wolff SP, Dean RT (1987) Glucose autoxidation and protein modification. The potential role of ‘autoxidative glycosylation’ in diabetes. Biochem J 245:243–250PubMed
82.
Mohanty P, Hamouda W, Garg R, Aljada A, Ghanim H, Dandona P (2000) Glucose challenge stimulates reactive oxygen species (ROS) generation by leucocytes. J Clin Endocrinol Metab 85:2970–2973
83.
Kobayashi K, Watanabe J, Umeda F, Nawata H (1995) Glycation accelerates the oxidation of low density lipoprotein by copper ions. Endocr J 42:461–465
84.
Bowie A, Owens D, Collins P, Johnson A, Tomkin GH (1993) Glycosylated low density lipoprotein is more sensitive to oxidation: implications for the diabetic patient? Atherosclerosis 102:63–67
85.
Caixàs A, Ordónez-Llanos J, De Leiva A, Payés A, Homs R, Pérez A (1997) Optimization of glycemic control by insulin therapy decreases the proportion of small dense LDL particles in diabetic patients. Diabetes 46:1207–1213
86.
Wägner AM, Jorba O, Rigla M et al (2003) Effect of improving glycemic control on low-density lipoprotein particle size in type 2 diabetes. Metabolism 52:1576–1578
87.
Soedamah-Muthu SS, Colhoun HM, Thomason MJ et al (2003) The effect of atorvastatin on serum lipids, lipoproteins and NMR spectroscopy defined lipoprotein subclasses in type 2 diabetic patients with ischaemic heart disease. Atherosclerosis 167:243–255
Metadata
Title
Clinical significance of the physicochemical properties of LDL in type 2 diabetes
Authors
P. G. Scheffer
T. Teerlink
R. J. Heine
Publication date
01-05-2005
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 5/2005
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-005-1736-0

Other articles of this Issue 5/2005

Diabetologia 5/2005 Go to the issue

Article

Dynamic change in adiposity from fetal to postnatal life is involved in the metabolic syndrome associated with reduced fetal growth

Article

No association between insulin gene variation and adult metabolic phenotypes in a large Finnish birth cohort

Erratum

Comparison of high-fat and high-protein diets with a high-carbohydrate diet in insulin-resistant obese women

Article

The risk of venous thromboembolism is markedly elevated in patients with diabetes

Article

Dietary manipulation of beta cell autoimmunity in infants at increased risk of type 1 diabetes: a pilot study

Article

Troglitazone causes acute mitochondrial membrane depolarisation and an AMPK-mediated increase in glucose phosphorylation in muscle cells
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits